UK markets closed
  • FTSE 100

    7,774.00
    -10.87 (-0.14%)
     
  • FTSE 250

    19,850.60
    -86.60 (-0.43%)
     
  • AIM

    867.10
    -2.06 (-0.24%)
     
  • GBP/EUR

    1.1344
    -0.0034 (-0.30%)
     
  • GBP/USD

    1.2320
    -0.0034 (-0.27%)
     
  • BTC-GBP

    18,826.72
    -79.36 (-0.42%)
     
  • CMC Crypto 200

    526.98
    +8.19 (+1.58%)
     
  • S&P 500

    4,044.18
    +26.41 (+0.66%)
     
  • DOW

    33,801.23
    +84.14 (+0.25%)
     
  • CRUDE OIL

    78.66
    +0.76 (+0.98%)
     
  • GOLD FUTURES

    1,943.40
    +4.20 (+0.22%)
     
  • NIKKEI 225

    27,327.11
    -106.29 (-0.39%)
     
  • HANG SENG

    21,842.33
    -227.40 (-1.03%)
     
  • DAX

    15,126.07
    -0.01 (-0.00%)
     
  • CAC 40

    7,086.98
    +4.97 (+0.07%)
     

Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023

NICOX
NICOX

Press Release

Nicox to Participate in Financial, Pharmaceutical Industry and Scientific Events in H1 2023



January 24, 2023 – release at 7:30 am CET
Sophia Antipolis, France



Nicox SA (Euronext Paris: FR0013018124, COX), an international ophthalmology company, today that members of the management team will participate in the following financial, pharmaceutical industry and scientific conferences in Europe and U.S. in the coming months:



Financial and Pharmaceutical Industry conferences



Members of the management team will be available for one-on-one meetings at these events.



Scientific conferences



About Nicox

Nicox SA is an international ophthalmology company developing innovative solutions to help maintain vision and improve ocular health. Nicox’s lead program in clinical development is NCX 470, a novel nitric oxide-donating bimatoprost, for lowering intraocular pressure in patients with open-angle glaucoma or ocular hypertension. The company is also conducting research on NCX 1728, a nitric oxide-donating phosphodiesterase 5 inhibitor, in retinal conditions. NCX 4251, a novel, patented, ophthalmic suspension of fluticasone propionate nanocrystals for topical ocular application for dry eye disease, is being developed by Ocumension Therapeutics in China under an exclusive license agreement and is available for partnering elsewhere. Nicox generates revenue from VYZULTA® in glaucoma, licensed exclusively worldwide to Bausch + Lomb, and ZERVIATE® in allergic conjunctivitis, licensed in multiple geographies, including to Eyevance Pharmaceuticals, LLC (a wholly-owned subsidiary of Santen Pharmaceutical Co., Ltd.), in the U.S. and Ocumension Therapeutics in the Chinese and in the majority of Southeast Asian markets.   

Nicox is headquartered in Sophia Antipolis, France, is listed on Euronext Paris (Compartment C: Mid Caps; Ticker symbol: COX) and is part of the CAC Healthcare, CAC Pharma & Bio and Next 150 indexes.

For more information on Nicox, its products or pipeline, please visit: www.nicox.com.

Analyst coverage



Bryan, Garnier & Co         Eric Yoo        Paris, France
Edison Investment Research        Pooya Hemami        London, UK
H.C. Wainwright & Co        Yi Chen        New York, U.S.
Kepler Cheuvreux        Arsene Guekam        Paris, France

 

The views expressed by analysts in their coverage of Nicox are those of the author and do not reflect the views of Nicox. Additionally, the information contained in their reports may not be correct or current. Nicox disavows any obligation to correct or to update the information contained in analyst reports.



Contacts

 



Nicox
Gavin Spencer
Executive Vice President, Chief Business Officer
& Head of Corporate Development
T +33 (0)4 97 24 53 00
communications@nicox.com



Investors & Media
United States & Europe
LifeSci Advisors, LLC
Sandya von der Weid
T +41 78 680 05 38
svonderweid@lifesciadvisors.com

Forward-Looking Statements

The information contained in this document may be modified without prior notice. This information includes forward-looking statements. Such forward-looking statements are not guarantees of future performance. These statements are based on current expectations or beliefs of the management of Nicox S.A. and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Nicox S.A. and its affiliates, directors, officers, employees, advisers or agents, do not undertake, nor do they have any obligation, to provide updates or to revise any forward-looking statements.

Risks factors which are likely to have a material effect on Nicox’s business are presented in the 3rd chapter of the ‘Document d’enregistrement universel, rapport financier annuel et rapport de gestion 2021’ filed with the French Autorité des Marchés Financiers (AMF) on April 29, 2022 whose first amendment has been filed with the AMF on May 19, 2022, in the 2nd chapter of the second amendment filed with the AMF on November 22, 2022 and in the 2nd chapter of the Securities noted filed with the AMF on November 22, 2022 which are available on Nicox’s website (www.nicox.com)

Nicox S.A.
Drakkar 2
Bât D, 2405 route des Dolines
06560 Valbonne, France
T +33 (0)4 97 24 53 00
F +33 (0)4 97 24 53 99

 

Attachment